中国汉族人群华法林药物基因组学剂量预测公式比较

被引:11
作者
祝锦
张微
张伟娟
王鹤尧
王辰
机构
[1] 首都医科大学附属北京朝阳医院
关键词
CYP2C9; VKORC1; 药物基因组学; 华法林;
D O I
暂无
中图分类号
R969 [临床药理学];
学科分类号
100602 ; 100706 ;
摘要
目的对目前已发表的7个华法林药物基因组学剂量预测公式在中国汉族人群中进行比较。方法选择服用华法林的静脉血栓栓塞患者302例,经签署知情同意书后,抽取静脉血,用ARMS(扩增阻滞突变系统)方法检测华法林药物基因组:CYP2C9*3、VKORC1 c.-1639G>A及VKORC1 c.1173C>T,采用拟合优度χ2检验判断各基因型频率是否符合Hardy-Wein-berg(哈迪.温伯格)平衡;并用Epidata13.0软件记录患者年龄、性别、体重等临床和遗传信息,按目前已发表的7个华法林药物基因组学剂量预测公式计算预测华法林稳定剂量,计算预测误差并对7组预测误差进行方差分析,统计学软件采用SPSS13.0,检验水准设定为0.05。计算预测剂量过高、过低和理想剂量所占百分数。结果在7个华法林药物基因组学剂量预测公式中,Anderson的公式平均预测误差绝对值最小,为0.112 mg,理想预测剂量所占百分数最高(72.5%)。Miao的公式平均预测误差绝对值1.607 mg,理想预测剂量所占百分数11.6%。IWPC华法林预测公式及其他公式平均预测误差绝对值在0.161~0.795 mg之间,理想预测剂量所占百分数相似,在33.4%~43%之间。结论本试验表明,在中国汉族人群中,Ander-son的华法林药物基因组学剂量预测公式的平均预测误差绝对值最小,理想预测剂量所占百分数最高,但方程的决定系数偏低还有待进一步研究以发现其他影响预测华法林剂量的因素。
引用
收藏
页码:1929 / 1934
页数:6
相关论文
共 8 条
[1]   Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing [J].
Roper, Nitin ;
Storer, Barry ;
Bona, Robert ;
Fang, Min .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (03) :283-291
[2]   Application of Akaike information criterion to evaluate warfarin dosing algorithm [J].
Harada, Takumi ;
Ariyoshi, Noritaka ;
Shimura, Hitoshi ;
Sato, Yasunori ;
Yokoyama, Iichiro ;
Takahashi, Kaori ;
Yamagata, Shin-ichi ;
Imamaki, Mizuho ;
Kobayashi, Yoshio ;
Ishii, Itsuko ;
Miyazaki, Masaru ;
Kitada, Mitsukazu .
THROMBOSIS RESEARCH, 2010, 126 (03) :183-190
[3]   Genetic determinants of warfarin dosing in the Han-Chinese population [J].
Lee, M. T. Michael ;
Chen, Chien-Hsiun ;
Chou, Ching-Heng ;
Lu, Liang-Suei ;
Chuang, Hui-Ping ;
Chen, Ying-Ting ;
Saleem, Amir N. ;
Wen, Ming-Shien ;
Chen, Jin-Jer ;
Wu, Jer-Yuarn ;
Chen, Yuan-Tsong .
PHARMACOGENOMICS, 2009, 10 (12) :1905-1913
[4]  
10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal[J] . Daniel Kurnik,Ronen Loebstein,Hillel Halkin,Eva Gak,Shlomo Almog.Pharmacogenomics . 2009 (12)
[5]  
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients[J] . Sheng-Wen Huang,Hai-Sheng Chen,Xian-Qun Wang,Ling Huang,Ding-Li Xu,Xiao-Jia Hu,Zhi-Hui Huang,Yong He,Kai-Ming Chen,Dao-Kang Xiang,Xiao-Ming Zou,Qiang Li,Li-Qin Ma,Hao-Fei Wang,Bao-Lin Chen,Liang Li,Yan-Kai Jia,Xiang-Min Xu.Pharmacogenetics and Genomics . 2009 (3)
[6]   Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].
Anderson, Jeffrey L. ;
Horne, Benjamin D. ;
Stevens, Scott M. ;
Grove, Amanda S. ;
Barton, Stephanie ;
Nicholas, Zachery P. ;
Kahn, Samera F. S. ;
May, Heidi T. ;
Samuelson, Kent M. ;
Muhlestein, Joseph B. ;
Carlquist, John F. .
CIRCULATION, 2007, 116 (22) :2563-2570
[7]  
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues[J] . Brian F. Gage,Lawrence J. Lesko.Journal of Thrombosis and Thrombolysis . 2008 (1)
[8]  
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients[J] . Liyan Miao,Jian Yang,Chenrong Huang,Zhenya Shen.European Journal of Clinical Pharmacology . 2007 (12)